mucopolysaccharidosis

(redirected from Mucopolysaccharidosis i)
Also found in: Dictionary, Thesaurus, Medical.
Related to Mucopolysaccharidosis i: Mucopolysaccharidosis iii

mucopolysaccharidosis

[¦myü·kō‚päl·ē‚sak·ə·rə′dō·səs]
(medicine)
Any of several inborn metabolic disorders involving mucopolysaccharides; the six types are MPS I, Hurler's syndrome; MPS II, Hunter's syndrome; MPS III, Sanfillipo's syndrome; MPS IV, Morquio's syndrome; MPS V, Scheil's syndrome; and MPS VI, Maroteaux-Lamy's syndrome.
References in periodicals archive ?
Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline on the basis of route of administration and molecule type.
Nasdaq and Swiss SWX New Market: BMRN) and Genzyme General (Nasdaq:GENZ) today announced positive results from a preliminary analysis of data from the Phase 3 clinical trial of Aldurazyme(TM) (laronidase), an investigational enzyme replacement therapy for patients with mucopolysaccharidosis I (MPS I).
This enzyme, which has completed a pivotal clinical trial and for which a Biologics License Application (BLA) is in progress, is used in enzyme replacement therapy for mucopolysaccharidosis I (MPS-I), an often fatal genetic disease afflicting young children.
a privately held biopharmaceutical company and Genzyme General (Nasdaq:GENZ) have formed a joint venture to develop and commercialize BioMarin's lead product candidate, (alpha)-L-iduronidase, a recombinant enzyme to treat the lysosomal storage disorder mucopolysaccharidosis I (MPS I).
Proceeds from the financing will be used to advance clinical trials currently underway for BioMarin's lead clinical programs, including a recombinant enzyme product, (alpha)-L-iduronidase, to treat a serious genetic disorder, mucopolysaccharidosis I (MPS I).
and Genzyme General (NASDAQ:GENZ) intend to form a joint venture to develop and commercialize BioMarin's lead product, a-L-iduronidase, a recombinant enzyme designed to treat the genetic disorder known as mucopolysaccharidosis I (MPS I).

Full browser ?